25.80 +0.18 (0.70%)
After hours: 6:59PM EST
|Bid||25.25 x 600|
|Ask||25.80 x 100|
|Day's Range||25.49 - 25.89|
|52 Week Range||21.03 - 29.93|
|PE Ratio (TTM)||42.00|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A few weeks ago, Boston Scientific announced that its expected launch of Lotus Heart Valve in the EU and U.S. in early 2018 will be delayed. This spooked investors somewhat, and has contributed to a more than 10% decline in the stock price since then.
Boston Scientific Corp. announced U.S. regulators have approved its Vercise Deep Brain Stimulation System to treat patients with Parkinson’s disease Monday, boosting its share price nearly 3 percent in after-hours trading. The device, which stimulates a specific area of the brain using implanted leads, was shown in a U.S. trial to help improve the number of waking hours per day in patients with the disease, according to the company. In another study in Europe, it helped patients achieve a 63 percent improvement in motor function over the course of a year, as measured by a common rating system to measure severity of Parkinson’s disease.
Shares of medical device maker Boston Scientific Corporation (NYSE: BSX ) received a top-notch rating Friday from Needham. The Analyst Needham analyst Mike Matson upgraded shares of Boston Scientific from ...
Boston Scientific (BSX) announced its deal to acquire Apama Medical and strengthen its electrophysiology portfolio on October 2, 2017.
Since the company's news of the delay in relaunch of Lotus Edge on November 28, 2017, Boston Scientific (BSX) stock has fallen ~7.8%.
According to Boston Scientific, the delay will have no material impact on the company's fiscal 4Q17 and 2017 results.
Boston Scientific (BSX) announces a delay in deadline for the commercial return of the LOTUS Edge Aortic Valve System in Europe. Following this news, share price declines.
Boston Scientific (BSX) announced the delay in the commercialization timelines of BSX's Lotus devices in Europe and the US on November 28, 2017.
Boston Scientific dipped Wednesday after announcing another delay for its heart-valve replacement product, called Lotus Edge.
Shares of the worldwide developer, manufacturer, and marketer of medical devices were sent lower on Tuesday after it delayed the commercialization of its Lotus Edge Aortic Valve System.
Boston Scientific’s Cardiovascular segment accounts for around 40% of the company’s value, according to our estimates.
Boston Scientific Corporation (NYSE: BSX ) announced Tuesday after the close a delay to earlier timelines that were established for commercialization of the LOTUS Edge Aortic Valve System in Europe and ...
Shares of Boston Scientific took an unexpected dive on Tuesday after the Marlborough-based medical device maker cancelled a scheduled appearance at an investor conference without explanation. Boston Scientific (BSX) pulled out of the annual Piper Jaffray healthcare conference in New York, where two of the company’s investor relations executives had been scheduled to participate in a question-and-answer session Tuesday morning.
Boston Scientific (BSX) fell to the bottom of the S&P 500 on Tuesday, after it pulled out of a scheduled conference appearance. Boston Scientific slid $2.12, or $7.4, to $26.42, while the S&P 500 rose 25.62 points, or 0.98%, to 2627.04, notching a new record close. As last as last week, Boston Scientific had been scheduled to appear at the Piper Jaffary Annual Healthcare Conference.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Boston Scientific Corp. Here are 5 ETFs with the largest exposure to BSX-US. Comparing the performance and risk of Boston Scientific Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Four months after losing its longtime chief financial officer to another drugmaker, Biogen has appointed a former Boston Scientific executive to that post. Cambridge-based Biogen (BIIB) said Tuesday that Jeffrey Capello will take over as CFO on Dec. 11. Before that, he founded and ran his own financial advisory firm in Boston, and held CFO roles at Ortho Clinical Diagnostics, Boston Scientific Corp. (BSX) and PerkinElmer (PKI).
In August of last year, yours truly here commented that fitness tracker company Fitbit Inc (NYSE:FIT) was a lost cause by catering to the consumer fitness market, and would only survive if it pivoted to being a full-blown medical device company. The response from loyal owners of FIT stock was…colorful, explaining such a thing could never happen, nor did it need to. Here we are 15 months later, and the FIT stock price is 60% less than its value then.
The Zacks Analyst Blog Highlights: Baxter International, BostonScientific, Intuitive Surgical and Becton and Dickinson
Considering Trump's growing focus on APAC, the region seems to be poised to yield accretive returns over the long term. Favorable MedTech trends in APAC hold promise.